MAP2K7 and metastatic melanoma: While MEK inhibitor treatment is associated with improved response rate, progression free-survival and overall survival in patients with B-RAF mutant metastatic melanoma, combined B-RAF and MEK inhibitor treatment seems to provide greater improvements in progression-free survival and overall survival compared with B-RAF inhibitor monotherapy [25].